Intervention Review

Cannabinoids for the treatment of dementia

  1. Sarada Krishnan1,*,
  2. Ruth Cairns2,
  3. Robert Howard3

Editorial Group: Cochrane Dementia and Cognitive Improvement Group

Published Online: 15 APR 2009

Assessed as up-to-date: 9 NOV 2008

DOI: 10.1002/14651858.CD007204.pub2

How to Cite

Krishnan S, Cairns R, Howard R. Cannabinoids for the treatment of dementia. Cochrane Database of Systematic Reviews 2009, Issue 2. Art. No.: CD007204. DOI: 10.1002/14651858.CD007204.pub2.

Author Information

  1. 1

    Maudsley Hospital, Mental Health of Older Adults, London, UK

  2. 2

    Institute of Psychiatry, Department of Psychological Medicine, London, UK

  3. 3

    Institute of Psychiatry, London, UK

*Sarada Krishnan, Mental Health of Older Adults, Maudsley Hospital, Denmark Hill, London, SE5 8AZ, UK.

Publication History

  1. Publication Status: New
  2. Published Online: 15 APR 2009


Cited in:


This article has been cited by:

  1. 1
    Hefei Wen, Jason M. Hockenberry, Janet R. Cummings, The effect of medical marijuana laws on adolescent and adult use of marijuana, alcohol, and other substances, Journal of Health Economics, 2015, 42, 64


  2. 2
    Ester Aso, Isidre Ferrer, Cannabinoids for treatment of Alzheimer’s disease: moving toward the clinic, Frontiers in Pharmacology, 2014, 5,


  3. 3
    David Cheng, Jac Kee Low, Warren Logge, Brett Garner, Tim Karl, Chronic cannabidiol treatment improves social and object recognition in double transgenic APPswe/PS1∆E9 mice, Psychopharmacology, 2014, 231, 15, 3009


  4. 4
    Andrew J. Hill, Claire M. Williams, Benjamin J. Whalley, Gary J. Stephens, Phytocannabinoids as novel therapeutic agents in CNS disorders, Pharmacology & Therapeutics, 2012, 133, 1, 79


  5. 5
    Cathy Payne, Philip J Wiffen, Suzanne Martin, Interventions for fatigue and weight loss in adults with advanced progressive illness, The Cochrane Library,